市場調查報告書
商品編碼
905942

難治性慢性咳嗽漱(CRC)- 市場洞察,流行病學,預測

Chronic Refractory Cough - Market Insight, Epidemiology and Market Forecast - 2030

出版日期: 按訂單生產 | 出版商: DelveInsight Business Research LLP | 英文 150 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的難治性慢性咳嗽漱(CRC)市場調查,疾病概要和現行的治療方法,新藥的簡介,整體及各國的市場趨勢,流行病學的預測,市場規模,患病數的變化與預測,未滿足需求,市場成長要素及障礙等資訊總括性彙整。

目錄

第1章 重要洞察

第2章 市場概要

  • 市場佔有率(成果值)
  • 市場佔有率(預測值)

第3章 疾病背景和概要

  • 簡介
  • 徵兆與症狀
  • 原因
  • 危險因素
  • 慢性咳嗽漱的機制
  • 慢性咳嗽漱的病理生理學
  • 難治性慢性咳嗽漱和其他的神經病變的相似性
  • 難治性慢性咳嗽漱的病因
  • 難治性慢性咳嗽漱的臨床性特徵
  • 診斷

第4章 流行病學和患者人口

  • 主要7個國家的難治性慢性咳嗽漱(CRC)患者數
  • 主要7個國家的難治性慢性咳嗽漱(CRC)診斷數

第5章 難治性慢性咳嗽漱的流行病學:各國

  • 美國
    • 假設和根據
    • 慢性咳嗽漱的患病數
    • 慢性咳嗽漱的患病數:性別
    • 難治性慢性咳嗽漱的患病數
    • 難治性慢性咳嗽漱的診斷數
    • 特發性肺纖維化(IPF)患者的難治性慢性咳嗽漱的患病數
  • 歐盟5國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第6章 難治性慢性咳嗽漱(CRC)的治療

  • 末梢性
    • TRP流通管道
    • 嘌呤受體
    • 電位門控鈉離子通道
  • 中樞性
    • Opiates (Morphine Sulphate/Codeine/Tramadol)
    • GABA相關化合物(Gabapentin,Pregabalin)
    • N-甲基-D-天冬氨酸(NMDA)受體
    • Amitriptyline
    • Tachykinin Receptor Antagonists
    • 尼古丁性乙醯膽鹼受體
  • 慢性咳嗽漱管理

第7章 美國的難治性慢性咳嗽漱(CRC)指南

第8章 未滿足需求

第9章 新藥

  • 關鍵交叉競爭
  • Gefapixant:Merck
    • 產品概要
    • 開發趨勢
    • 臨床開發
    • 產品簡介
  • Orvepitant Maleate:Nerre Therapeutics
  • BLU-5937:Bellus Health
  • Bradanicline:Attenua
  • RVT-1601:Respivant Sciences
  • S-600918:鹽野義製藥

第10章 主要7個國家的難治性慢性咳嗽漱(CRC)市場

  • 主要調查結果
  • 主要7個國家的市場規模

第11章 美國市場預測

  • 美國的市場規模
    • 整體市場規模
    • 市場規模:各治療藥物

第12章 市場預測歐洲5個國家

  • 德國
    • 整體市場規模
    • 市場規模:各治療藥物
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第13章 市場成長要素

第14章 市場障礙

第15章 附錄

  • 調查方法

第16章 DelveInsight的服務內容

第17章 免責聲明

第18章 關於DelveInsight

目錄
Product Code: DIMI0626

DelveInsight's " Chronic Refractory Cough - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Chronic Refractory Cough, historical and forecasted epidemiology as well as the Chronic Refractory Cough market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Chronic Refractory Cough market report provides current treatment practices, emerging drugs, Chronic Refractory Cough market share of the individual therapies, current and forecasted Chronic Refractory Cough market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Chronic Refractory Cough treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Chronic Refractory Cough Disease Understanding and Treatment Algorithm

The DelveInsight Chronic Refractory Cough market report gives a thorough understanding of the Chronic Refractory Cough by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Chronic Refractory Cough.

Treatment

It covers the details of conventional and current medical therapies available in the Chronic Refractory Cough market for the treatment of the condition. It also provides Chronic Refractory Cough treatment algorithms and guidelines in the United States, Europe, and Japan.

Chronic Refractory Cough Epidemiology

The Chronic Refractory Cough epidemiology division provide insights about historical and current Chronic Refractory Cough patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Chronic Refractory Cough epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Chronic Refractory Cough Epidemiology

The epidemiology segment also provides the Chronic Refractory Cough epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Chronic Refractory Cough Drug Chapters

Drug chapter segment of the Chronic Refractory Cough report encloses the detailed analysis of Chronic Refractory Cough marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Chronic Refractory Cough clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Chronic Refractory Cough treatment.

Chronic Refractory Cough Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Chronic Refractory Cough treatment.

Chronic Refractory Cough Market Outlook

The Chronic Refractory Cough market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Chronic Refractory Cough market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Chronic Refractory Cough market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Chronic Refractory Cough market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Chronic Refractory Cough market in 7MM.

The United States Market Outlook

This section provides the total Chronic Refractory Cough market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Chronic Refractory Cough market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Chronic Refractory Cough market size and market size by therapies in Japan is also mentioned.

Chronic Refractory Cough Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Chronic Refractory Cough market or expected to get launched in the market during the study period 2017-2030. The analysis covers Chronic Refractory Cough market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Chronic Refractory Cough Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Chronic Refractory Cough key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Chronic Refractory Cough emerging therapies.

Reimbursement Scenario in Chronic Refractory Cough

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Chronic Refractory Cough domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Chronic Refractory Cough market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Chronic Refractory Cough Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Chronic Refractory Cough, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Chronic Refractory Cough epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Refractory Cough are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Chronic Refractory Cough market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chronic Refractory Cough market

Report Highlights

  • In the coming years, Chronic Refractory Cough market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Refractory Cough R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Chronic Refractory Cough. Launch of emerging therapies will significantly impact the Chronic Refractory Cough market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Chronic Refractory Cough
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Chronic Refractory Cough Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Chronic Refractory Cough Pipeline Analysis
  • Chronic Refractory Cough Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Chronic Refractory Cough Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Chronic Refractory Cough Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Chronic Refractory Cough Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Chronic Refractory Cough market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Chronic Refractory Cough total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Chronic Refractory Cough market size during the forecast period (2017-2030)?
  • At what CAGR, the Chronic Refractory Cough market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Chronic Refractory Cough market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Chronic Refractory Cough market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Chronic Refractory Cough?
  • What is the historical Chronic Refractory Cough patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Chronic Refractory Cough in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Chronic Refractory Cough?
  • Out of all 7MM countries, which country would have the highest prevalent population of Chronic Refractory Cough during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Chronic Refractory Cough treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Chronic Refractory Cough in the USA, Europe, and Japan?
  • What are the Chronic Refractory Cough marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Chronic Refractory Cough?
  • How many therapies are developed by each company for Chronic Refractory Cough treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Chronic Refractory Cough treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Chronic Refractory Cough therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Chronic Refractory Cough and their status?
  • What are the key designations that have been granted for the emerging therapies for Chronic Refractory Cough?
  • What are the global historical and forecasted market of Chronic Refractory Cough?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Chronic Refractory Cough market
  • To understand the future market competition in the Chronic Refractory Cough market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic Refractory Cough in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic Refractory Cough market
  • To understand the future market competition in the Chronic Refractory Cough market

Table of Contents

1. Key Insights

2. Executive Summary of Chronic Refractory Cough

3. Competitive Intelligence Analysis for Chronic Refractory Cough

4. Chronic Refractory Cough: Market Overview at a Glance

  • 4.1. Chronic Refractory Cough Total Market Share (%) Distribution in 2017
  • 4.2. Chronic Refractory Cough Total Market Share (%) Distribution in 2030

5. Chronic Refractory Cough: Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Chronic Refractory Cough Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Chronic Refractory Cough Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Chronic Refractory Cough Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Chronic Refractory Cough Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Chronic Refractory Cough Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Chronic Refractory Cough Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Chronic Refractory Cough Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Chronic Refractory Cough Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Chronic Refractory Cough Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Chronic Refractory Cough Treatment and Management
  • 8.2. Chronic Refractory Cough Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Chronic Refractory Cough Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Chronic Refractory Cough: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Chronic Refractory Cough Market Size in 7MM
  • 13.3. Chronic Refractory Cough Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Chronic Refractory Cough Total Market Size in the United States
    • 15.1.2. Chronic Refractory Cough Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Chronic Refractory Cough Total Market Size in Germany
    • 15.3.2. Chronic Refractory Cough Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Chronic Refractory Cough Total Market Size in France
    • 15.4.2. Chronic Refractory Cough Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Chronic Refractory Cough Total Market Size in Italy
    • 15.5.2. Chronic Refractory Cough Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Chronic Refractory Cough Total Market Size in Spain
    • 15.6.2. Chronic Refractory Cough Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Chronic Refractory Cough Total Market Size in the United Kingdom
    • 15.7.2. Chronic Refractory Cough Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Chronic Refractory Cough Total Market Size in Japan
    • 15.8.3. Chronic Refractory Cough Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Chronic Refractory Cough

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Chronic Refractory Cough Epidemiology (2017-2030)
  • Table 2 : 7MM Chronic Refractory Cough Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Chronic Refractory Cough Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Chronic Refractory Cough Epidemiology in Germany (2017-2030)
  • Table 6 : Chronic Refractory Cough Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Chronic Refractory Cough Epidemiology in France (2017-2030)
  • Table 8 : Chronic Refractory Cough Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Chronic Refractory Cough Epidemiology in Italy (2017-2030)
  • Table 10 : Chronic Refractory Cough Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Chronic Refractory Cough Epidemiology in Spain (2017-2030)
  • Table 12 : Chronic Refractory Cough Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Chronic Refractory Cough Epidemiology in the UK (2017-2030)
  • Table 14 : Chronic Refractory Cough Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Chronic Refractory Cough Epidemiology in Japan (2017-2030)
  • Table 16 : Chronic Refractory Cough Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Chronic Refractory Cough Epidemiology (2017-2030)
  • Figure 2 : 7MM Chronic Refractory Cough Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Chronic Refractory Cough Epidemiology in the United States (2017-2030)
  • Figure 4 : Chronic Refractory Cough Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Chronic Refractory Cough Epidemiology in Germany (2017-2030)
  • Figure 6 : Chronic Refractory Cough Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Chronic Refractory Cough Epidemiology in France (2017-2030)
  • Figure 8 : Chronic Refractory Cough Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Chronic Refractory Cough Epidemiology in Italy (2017-2030)
  • Figure 10 : Chronic Refractory Cough Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Chronic Refractory Cough Epidemiology in Spain (2017-2030)
  • Figure 12 : Chronic Refractory Cough Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Chronic Refractory Cough Epidemiology in the UK (2017-2030)
  • Figure 14 : Chronic Refractory Cough Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Chronic Refractory Cough Epidemiology in Japan (2017-2030)
  • Figure 16 : Chronic Refractory Cough Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)